• LAST PRICE
    5.6591
  • TODAY'S CHANGE (%)
    Trending Down-0.1010 (-1.7534%)
  • Bid / Lots
    5.4200/ 1
  • Ask / Lots
    6.3800/ 1
  • Open / Previous Close
    5.8650 / 5.7601
  • Day Range
    Low 5.5500
    High 6.0178
  • 52 Week Range
    Low 5.1000
    High 26.2455
  • Volume
    8,667
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 5.7601
TimeVolumeDFFN
09:36 ET4005.865
09:39 ET30006.0178
09:56 ET2005.6408
10:03 ET1005.7361
10:53 ET2005.55
11:27 ET5015.55
11:38 ET1005.5501
12:25 ET11055.6
12:41 ET2005.6
12:56 ET1005.58
01:08 ET1005.6
01:10 ET3005.65
01:14 ET1005.625
01:19 ET1005.6217
01:21 ET1005.62
01:24 ET1005.65
02:02 ET1605.6219
02:31 ET4005.5519
02:42 ET1005.5876
03:52 ET1005.6591
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDFFN
Diffusion Pharmaceuticals Inc
11.5M
-0.5x
---
United StatesPTIX
Protagenic Therapeutics Inc
11.6M
-3.0x
---
United StatesALLR
Allarity Therapeutics Inc
11.3M
-0.3x
---
United StatesPHGE
Biomx Inc
11.8M
-0.3x
---
United StatesPKTX
ProtoKinetix Inc
10.7M
-3.7x
---
United StatesSKYE
Skye Bioscience Inc
12.5M
-1.1x
---
As of 2022-09-24

Company Information

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate, Trans Sodium Crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The Company is focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia with a particular near-term focus on hypoxic solid tumors. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers.

Contact Information

Headquarters
300 EAST MAIN STREET, SUITE 201CHARLOTTESVILLE, VA, United States 22902
Phone
434-220-0718
Fax
434-220-0722

Executives

President, Chief Executive Officer, Director
Robert Cobuzzi
Chief Financial Officer
William Hornung
General Counsel, Corporate Secretary
William Elder
Chief Medical Officer
Christopher Galloway
Independent Director
Robert Adams

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$11.5M
Revenue (TTM)
$0.00
Shares Outstanding
2.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.53
EPS
$-12.11
Book Value
$17.13
P/E Ratio
-0.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.